A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Postmenopausal Clinical Trial

Official title:
A Randomized, Double-Blind, International Multicentre, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized at 1:1 to either the experiment group (HLX14) or the control group (Prolia®) based on stratification factors (BMI (< 25, 25-30, > 30) and geographic region (Asian or non-Asian)). The study includes screening period (28 days), treatment period (total 546 days, contain treatment period 1: D1-D364, treatment period 2: D365-D546), and an end-of-study visit (D547).

Clinical Trial Description

- Screening period: From Day -28 to -1, all female with postmenopausal osteoporosis subjects at high risk of fracture sign the informed consent form (ICF) and undergo relevant tests. Those who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned into either experiment group (HLX14) or control group (Prolia®) at 1:1 and then enter the treatment period. Vitamin D and calcium supplementation is allowed during the screening period. - Treatment period: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)). Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 or Prolia® 60mg on D1 and D183. Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14. Subjects in the HLX14 arm will be continue with a third dose of HLX14. - During the treatment period, subjects should taking at least 1000 mg of calcium daily and at least 400 IU of vitamin D daily until the end of study. (Dose will be adjusted by the investigator based on serum calcium) - End-of-study visit: The end-of-study visit will be conducted on D547 of the study or premature withdrawal. Only serious adverse events related to the investigational product will be recorded thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05352516
Study type	Interventional
Source	Shanghai Henlius Biotech
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 17, 2022
Completion date	August 10, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02235051` - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors	N/A
Completed	`NCT01635413` - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)	N/A
Completed	`NCT00701337` - Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route	Phase 4
Recruiting	`NCT04705623` - Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women	N/A
Withdrawn	`NCT03238703` - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer	Phase 4
Completed	`NCT03756272` - Stellate Ganglion Block to Reduce Hot Flushes	N/A
Recruiting	`NCT03953157` - Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors	N/A
Completed	`NCT00338728` - Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT01482702` - Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors	N/A
Not yet recruiting	`NCT05009238` - Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women	N/A
Terminated	`NCT01842217` - Validation of [18F]FES for Imaging of Brain Estrogen Receptors	N/A
Completed	`NCT01172574` - Motor Control Exercise in Osteoporotic Women	N/A
Completed	`NCT00530582` - Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women	Phase 4
Completed	`NCT01825785` - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)	Phase 1
Completed	`NCT04364061` - Post Exercise Substrate Oxidation, Appetite and Energy Intakes in Overweight/Obese Postmenopausal Women (EScAPE)	N/A
Completed	`NCT03180294` - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer	Phase 2
Recruiting	`NCT06445842` - Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women	N/A
Completed	`NCT01753908` - Broccoli Sprout Extract in Treating Patients With Breast Cancer	Early Phase 1
Not yet recruiting	`NCT06377631` - Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity	N/A
Recruiting	`NCT06228768` - Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer	N/A